tetano
Editor, Senior Moderator
J Control Release. 2015 May 21. pii: S0168-3659(15)00577-5. doi: 10.1016/j.jconrel.2015.05.278. [Epub ahead of print]
[h=1]Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.[/h] Kim MC[SUP]1[/SUP], Lee JW[SUP]2[/SUP], Choi HJ[SUP]3[/SUP], Lee YN[SUP]4[/SUP], Hwang HS[SUP]4[/SUP], Lee J[SUP]5[/SUP], Kim C[SUP]5[/SUP], Lee JS[SUP]6[/SUP], Montemagno C[SUP]3[/SUP], Prausnitz MR[SUP]2[/SUP], Kang SM[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] A broadly cross-protective influenza vaccine that can be administrated by a painless self-immunization method would be a value as a potential universal mass vaccination strategy. This study developed a minimally-invasive microneedle (MN) patch for skin vaccination with virus-like particles containing influenza virus heterologous M2 extracellular (M2e) domains (M2e5x VLPs) as a universal vaccine candidate without adjuvants. The stability of M2e5x VLP-coated microneedles was maintained for 8weeks at room temperature without losing M2e antigenicity and immunogenicity. MN skin immunization induced strong humoral and mucosal M2e antibody responses and conferred cross-protection against heterosubtypic H1N1, H3N2, and H5N1 influenza virus challenges. In addition, M2e5x VLP MN skin vaccination induced T-helper type 1 responses such as IgG2a isotype antibodies and IFN-γ producing cells at higher levels than those by conventional intramuscular injection. These potential immunological and logistic advantages for skin delivery of M2e5x VLP MN vaccines could offer a promising approach to develop an easy-to-administer universal influenza vaccine.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Cross-protection; Influenza universal vaccine; M2e5x VLPs; Microneedles
PMID: 26003039 [PubMed - as supplied by publisher]
[h=1]Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.[/h] Kim MC[SUP]1[/SUP], Lee JW[SUP]2[/SUP], Choi HJ[SUP]3[/SUP], Lee YN[SUP]4[/SUP], Hwang HS[SUP]4[/SUP], Lee J[SUP]5[/SUP], Kim C[SUP]5[/SUP], Lee JS[SUP]6[/SUP], Montemagno C[SUP]3[/SUP], Prausnitz MR[SUP]2[/SUP], Kang SM[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] A broadly cross-protective influenza vaccine that can be administrated by a painless self-immunization method would be a value as a potential universal mass vaccination strategy. This study developed a minimally-invasive microneedle (MN) patch for skin vaccination with virus-like particles containing influenza virus heterologous M2 extracellular (M2e) domains (M2e5x VLPs) as a universal vaccine candidate without adjuvants. The stability of M2e5x VLP-coated microneedles was maintained for 8weeks at room temperature without losing M2e antigenicity and immunogenicity. MN skin immunization induced strong humoral and mucosal M2e antibody responses and conferred cross-protection against heterosubtypic H1N1, H3N2, and H5N1 influenza virus challenges. In addition, M2e5x VLP MN skin vaccination induced T-helper type 1 responses such as IgG2a isotype antibodies and IFN-γ producing cells at higher levels than those by conventional intramuscular injection. These potential immunological and logistic advantages for skin delivery of M2e5x VLP MN vaccines could offer a promising approach to develop an easy-to-administer universal influenza vaccine.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Cross-protection; Influenza universal vaccine; M2e5x VLPs; Microneedles
PMID: 26003039 [PubMed - as supplied by publisher]